Get started
Work

361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER

Year: 2022
Type: article
DOI: 10.1016/j.annonc.2022.07.499
Authors: C. Wu, J.H. Strickler, A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, A.S. Paulson, J. Hubbard, A. Coveler, C. Fountzilas, A. Kardosh, P.M. Kasi, H.J. Lenz, K.K. Ciombor, M.E. Elez Fernandez, L-I. Hsu, M. Stecher, K. Zhao, T. Bekaii-Saab
Institutions: Mayo Clinic Comprehensive Cancer Center (Arizona), Duke Medical Center, Memorial Sloan Kettering Cancer Center, University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Hôpital Saint-Antoine, Dana-Farber Cancer Institute, Universitair Ziekenhuis Leuven, KU Leuven, Mayo Clinic, University of Washington, Fred Hutch Cancer Center, Roswell Park Comprehensive Cancer Center, Oregon Health & Science University, Weill Cornell Medicine, USC Norris Comprehensive Cancer Center, Vanderbilt University Medical Center, Universitat Autònoma de Barcelona, Centro de Investigación Biomédica en Red de Cáncer, Vall d'Hebron Institute of Oncology, Seagen (United States), Mayo Clinic Hospital
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4295817297
FWCI:
Cites:
Cited by: 1
Related to: 10